$31.23
-0.03 (-0.10%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-11.28%
1Y
+45.80%
YTD
-7.74%
Open$31.85
Previous Close$31.26
Day High$32.34
Day Low$30.65
52W High$39.28
52W Low$20.50
Volume—
Avg Volume1.64M
Market Cap2.97B
P/E Ratio—
EPS$-1.60
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$34.24
Below
SMA 200
$27.52
Above
RSI (14)
49.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
25 analysts
Price Target
+276.8% upside
Current
$31.23
$31.23
Target
$117.67
$117.67
$81.99
$117.67 avg
$158.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 235.02M | 144.59M | 384.15M |
| Net Income | -122,172,328 | -67,648,022 | -80,984,777 |
| Profit Margin | -52.0% | -49.4% | -21.1% |
| EBITDA | -168,287,651 | -98,359,338 | -85,173,040 |
| Free Cash Flow | — | — | -100,075,430 |
| Rev Growth | +62.5% | +62.5% | -7.8% |
| Debt/Equity | — | — | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $230.01 | +6.25% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $344.72 | +2.11% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.87 | +0.90% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $466.79 | +3.36% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $612.50 | +0.42% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.41 | +2.99% | 64.3 | 37.13B |